Lakefront Biotherapeutics NV (LKFT) stock
LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Financials through fiscal 2025, year ended Dec 31, 2025Score 7/30
$34.39−0.40 (-1.15%)
Close on Nov 17, 2026Market cap $2.27BP/E 6.4Yield –
Lakefront Biotherapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Lakefront Biotherapeutics's price to sales ratio was 1.8× on Nov 11, 2026, against 6.5× a year earlier. Over the last 5 years it ranged from 1.4× to 15.6×, with a median of 7.2×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.8× | −4.9 |
| 2025 | Dec 31, 2025 | 6.7× | −0.6 |
| 2024 | Dec 31, 2024 | 7.3× | −2.7 |
| 2023 | Dec 29, 2023 | 10.0× | −1.6 |
| 2022 | Dec 30, 2022 | 11.6× | +5.0 |
| 2021 | Dec 31, 2021 | 6.6× | +1.0 |
| 2020 | Dec 31, 2020 | 5.6× | −28.9 |
| 2019 | Dec 31, 2019 | 34.5× | +3.3 |
| 2018 | Dec 31, 2018 | 31.2× | +2.7 |
| 2017 | Dec 29, 2017 | 28.5× | −26.4 |
| 2016 | Dec 30, 2016 | 54.9× | – |
See a number that looks wrong?